A 2-year Study of Patients With Schizophrenia Who Are Treated With Long-acting Injectable Risperidone.

NCT ID: NCT00261430

Last Updated: 2011-05-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 650 participants
• Study Classification: INTERVENTIONAL
• Study Completion Date: 2004-10-31

Brief Summary

The purpose of this study is to examine treatment practices of adult schizophrenia patients by their own doctors, and to assess patient outcomes when treated with long-acting risperidone injection over a two-year period of observation.

Detailed Description

Controlled clinical trials for treating schizophrenia often involve selected patients with common characteristics. It is recognized that schizophrenia are much more diverse than those in the clinical setting, and that physician's prescribing practices may vary. The objective of the study is to examine treatment practices for adult schizophrenic patients by their own physicians, and to assess patient outcomes when treated with long-acting risperidone injection. This is a 2-year, prospective, multi-center, longitudinal, observational study in adults with schizophrenia. Physicians will determine the appropriate treatment for their patients, according to their usual practice. Patients starting treatment with long-acting risperidone injections and meeting all the study criteria may enroll in the study. Patients will continue their treatment according to usual care by their physicians. Patients will be asked questions at baseline and every three months for a period of two years to assess: efficacy of the medication, how well the patient is functioning, use of healthcare resources (e.g., emergency room visits, hospitalizations) patient work status, quality of life and patient satisfaction with the medicine. Safety will be monitored throughout the study. A dose of 25, 37.5 or 50 mg of risperidone, administered every 2 weeks by intramuscular injection.

Conditions

Schizophrenia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

GAIN Acceptance Approach

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

• Diagnosis of schizophrenia
• long-term use of antipsychotic medication and taking any oral antipsychotic for 4 weeks before the study
• stable with respect to disease symptoms and other medical conditions
• if female, using birth control.

Exclusion Criteria

• At risk to self or others
• use of injectable antipsychotics within the past 6 months, of clozapine, or of investigational drugs within 30 days
• considered to be resistant to treatment
• pregnant or breast-feeding
• not using birth control.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Janssen, LP

INDUSTRY

Sponsor Role: lead

Principal Investigators

Janssen, LP Clinical Trial

Role: STUDY_DIRECTOR

Janssen, LP

Related Links

http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=347&filename=CR002893_CSR.pdf

Schizophrenia Treatment Acceptance Response Trial

Other Identifiers

CR002893

Identifier Type: -

Identifier Source: org_study_id